Dermatology Biotech Bambusa Slides 7% After $168.9 Million IPO

Bambusa Therapeutics Inc. raised $168.9 million in its initial public offering. The early-stage biotech company develops treatments for dermatology and autoimmune diseases. Bambusa's shares declined 7% on their first day of trading.

• Bloomberg — Dermatology Biotech Bambusa Slides 7% After $168.9 Million IPO

Next story